BioCatalystWatch
DNLIWorkspace / DNLI / OverviewCompany library
Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI)

Website

Price
Market cap
Next catalystExpected 2026Zafinofusp alfa (DNL126) — Phase 1/2 · Study completionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

DNL151 (BIIB122)

LRRK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL628

MAPT (tau)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zafinofusp alfa (DNL126)

Transferrin receptor (TfR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

DNL593

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL921

Amyloid beta × TfR

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL952

TfR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Zafinofusp alfa (DNL126)

Transferrin receptor (TfR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

DNL628

MAPT (tau)

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL593

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL151 (BIIB122)

LRRK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL952

TfR

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL921

Amyloid beta × TfR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Tividenofusp alfa

Transferrin receptor (TfR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNL422

SNCA / α-synuclein

DNL622

DNL975

LRRK2

PreINDP1P2P3FilingApproved
DNL111

Partner / License out

Eclitasertib (SAR443122/DNL758)

RIPK1

PreINDP1P2P3FilingApproved
Eclitasertib (SAR443122/DNL758)

RIPK1

PreINDP1P2P3FilingApproved

Approved / commercial

Transferrin receptor (TfR) × Mannose-6-phosphate receptor

Approved

PreINDP1P2P3FilingApproved

History / paused

DNL151 (BIIB122)

LRRK2

PreINDP1P2P3FilingApproved

eIF2B

PreINDP1P2P3FilingApproved

RIPK1

PreINDP1P2P3FilingApproved

RIPK1

PreINDP1P2P3FilingApproved

TREM2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

DNLI PR & News

PR & News

DNLI SEC archive